Kiyohiro Ando1,2, Kazuyuki Hamada3, Makoto Watanabe1,2, Ryotaro Ohkuma1,2,3, Midori Shida1,2, Rie Onoue1,2, Yutaro Kubota3, Hiroto Matsui3, Tomoyuki Ishiguro3, Yuya Hirasawa3, Hirotsugu Ariizumi3, Junji Tsurutani3,4, Kiyoshi Yoshimura2,3, Takuya Tsunoda3, Shinichi Kobayashi2, Satoshi Wada5,2,3. 1. Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan. 2. Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan. 3. Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan. 4. Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan. 5. Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan st-wada@med.showa-u.ac.jp.
Abstract
BACKGROUND/AIM: Cancer immune therapy by immune checkpoint inhibitors (ICIs) is a promising therapeutic strategy for various cancer types. Among ICIs, anti-programmed cell death protein-1 (PD1) and anti-programmed death-ligand 1 (PD-L1) antibodies have shown a remarkable clinical benefit. The present study aimed to address the functional and clinical significance of serum levels of soluble PD-L1 (sPD-L1) in patients. MATERIALS AND METHODS: A total of 21 patients, 11 with NSCLC, nine with gastric cancer and one with bladder cancer, who underwent anti-PD-1 therapy were evaluated for sPD-L1 concentration by ELISA analyses at diagnosis and after treatment. RESULTS: Pretreatment levels of sPD-L1 in patients who received ICIs were not remarkably correlated with the overall survival of these patients (r=0.3394, p=0.1323). Reduction of plasma sPD-L1 level was significantly correlated with tumor regression in patients administered four cycles of treatment (p<0.05). CONCLUSION: sPD-L1 might be derived and secreted from tumors and might be useful to identify primary responders to ICIs at a relatively early treatment timepoint. Copyright
BACKGROUND/AIM: Cancer immune therapy by immune checkpoint inhibitors (ICIs) is a promising therapeutic strategy for various cancer types. Among ICIs, anti-programmed cell death protein-1 (PD1) and anti-programmed death-ligand 1 (PD-L1) antibodies have shown a remarkable clinical benefit. The present study aimed to address the functional and clinical significance of serum levels of soluble PD-L1 (sPD-L1) in patients. MATERIALS AND METHODS: A total of 21 patients, 11 with NSCLC, nine with gastric cancer and one with bladder cancer, who underwent anti-PD-1 therapy were evaluated for sPD-L1 concentration by ELISA analyses at diagnosis and after treatment. RESULTS: Pretreatment levels of sPD-L1 in patients who received ICIs were not remarkably correlated with the overall survival of these patients (r=0.3394, p=0.1323). Reduction of plasma sPD-L1 level was significantly correlated with tumor regression in patients administered four cycles of treatment (p<0.05). CONCLUSION: sPD-L1 might be derived and secreted from tumors and might be useful to identify primary responders to ICIs at a relatively early treatment timepoint. Copyright
Authors: Tatiana Cunha Pereira; Paulo Rodrigues-Santos; Jani Sofia Almeida; Fábio Rêgo Salgueiro; Ana Raquel Monteiro; Filipa Macedo; Rita Félix Soares; Isabel Domingues; Paula Jacinto; Gabriela Sousa Journal: Med Oncol Date: 2021-03-31 Impact factor: 3.064
Authors: Jacob J Orme; Elizabeth Ann L Enninga; Fabrice Lucien-Matteoni; Heather Dale; Edwin Burgstaler; Susan M Harrington; Matthew K Ball; Aaron S Mansfield; Sean S Park; Mathew S Block; Svetomir N Markovic; Yiyi Yan; Haidong Dong; Roxana S Dronca; Jeffrey L Winters Journal: J Immunother Cancer Date: 2020-08 Impact factor: 12.469